Sentinel lymph node dissection (SLND) is a standard axillary staging technique in breast cancer and intraoperative sentinel lymph node (SLN) assessment is important for decision-making regarding additional treatment and reconstruction. This study 
Z0011 trial demonstrated that completion axillary lymph node dissection (CLND) may be omitted in clinically node negative patients undergoing lumpectomy who are found to have fewer than three positive SLNs and who are planned for adjuvant whole breast radiotherapy. 3 There were no differences in local control or survival between patients who underwent CLND compared to those who did not. As a result, assessment of SLNs in this cohort is now deferred to permanent section at many centers, including our own. 4 For those patients with a positive SLN who fall outside of the Z0011 selection criteria, however, further axillary surgery would typically still be recommended. Thus, intraoperative SLN assessment continues to be a valuable tool in intraoperative decision-making regarding additional axillary surgery. In particular, patients undergoing total mastectomy and those who receive neoadjuvant chemotherapy do not meet the Z0011 criteria and an intraoperative decision to perform CLND is often based on the results of immediate assessment of the SLNs. In addition to avoiding another surgery, the intraoperative results of the SLN can also be helpful for patients who desire immediate reconstruction following total mastectomy as the status of the axilla is a major determinant of post-mastectomy radiotherapy which can influence the options for reconstruction. As the indications for SLND continue to expand, knowledge of factors which affect the accuracy of intraoperative SLN assessment will be helpful, particularly in regard to intraoperative decision-making.
Reported sensitivity rates of intraoperative SLN evaluation for breast cancer range from 58% to 72%. [5] [6] [7] A number of clinicopathologic and technique-related factors, such as tumor histology, size of the metastatic focus, number of SLNs retrieved, and method of intraoperative assessment have been shown to affect the accuracy of intraoperative SLN evaluation. 6, 8, 9 There are few reports on the accuracy of intraoperative SLN assessment after neoadjuvant therapy. The effects of chemotherapy-related cellular and stromal changes on intraoperative SLN analysis are not well-understood.
This study was undertaken to evaluate the effects of various disease and treatment-related variables, including neoadjuvant therapy, on the accuracy of intraoperative SLN assessment in patients presenting with clinically node negative breast cancer. Axillary SLN mapping was performed using radiocolloid and/or isosulfan blue dye, according to surgeon preference. All identified SLNs were sent to pathology for detailed evaluation. Once a metastatic lymph node had been identified on intraoperative evaluation, remaining SLNs for that patient were processed by permanent section only.
| ME TH ODS
Intraoperative SLN evaluation was performed using frozen section analysis or touch preparation with frozen section analysis. Our group has previously reported superior sensitivity for SLN metastases with frozen section evaluation compared to touch imprint cytology and no longer routinely performs touch preparation alone. 6 Therefore, patients whose SLNs were evaluated intraoperatively with only touch preparation were excluded. SLNs were bisected if they measured <0.5 cm in greatest diameter and sectioned at 2-mm intervals along the short axis if they measured >0.5 cm. Touch imprints and/or frozen sections were prepared from both cut surfaces of lymph node sections and then stained with hematoxylin and eosin (H&E). For the permanent section analysis, paraffin blocks were sectioned at 5 lm intervals to produce two sections for H&E examination and one section for immunostaining for pancytokeratins if H&E sections were negative for metastases.
Results of the intraoperative evaluation were compared to results of the final pathologic evaluation of permanent sections. SLNs containing metastases that were >0. P-values were considered significant at the 5% level.
Multivariate models were fit using all covariates that were statistically significant on univariate analysis as well as covariates felt to be of clinical significance. No model selection was performed and no statistical adjustment was made for the multiplicity of testing. The association between covariates of interest and neoadjuvant treatment category was assessed using Fisher's exact test.
| RESULTS
A total of 681 patients who were clinically node negative and who underwent SLND with intraoperative frozen section analysis of their There were 18 patients with ITC clusters in our cohort, and all were considered node-negative in the data analysis described above. can be sparse and difficult to identify.
Overall, the presence of micrometastases was associated with a greater than eightfold higher FN rate on univariate analysis, a finding which persisted on multivariate analysis. Of the SLN-positive patients in our series, 39% in the neoadjuvant therapy group had micrometastases vs 32% in the no-neoadjuvant therapy group. When we looked specifically at the neoadjuvant therapy group, we performed a subset analysis to identify factors associated with FN events and only SLN metastasis size was found to be a significant predictor. Other series showing lower sensitivity of both frozen section and touch imprint cytology for micrometastases in the non-neoadjuvant treatment population further support this. 7, 10 In so far as disease-related variables are concerned (favorable histology, lobular histology, micrometastasis), a higher index of suspicion by the pathologist may improve accuracy of intraoperative frozen section evaluation in these cases. 18 In addition, targeted axillary dissection has been proposed as a novel approach to accurately stage patients with node positive disease after neoadjuvant chemotherapy. 19 Building on these results, two additional cooperative group trials are underway to examine whether additional axillary treatment is warranted for clinically node positive patients after neoadjuvant chemotherapy and SLN biopsy. In the NSABP B-51/ RTOG 1304 trial, patients who convert to a negative SLN are randomized to receive radiotherapy or no radiotherapy to the axilla. 20 In the Alliance A11202 trial, patients with persistent SLN metastases are randomized to either CLND or no CLND but with nodal radiotherapy for all patients. 21 Randomization for CLND may be based on either final pathology or intraoperative assessment of the SLN. These studies illustrate the recent trend toward minimizing axillary surgery for node-positive patients treated with neoadjuvant therapy. For these patients, immediate assessment of the SLN will be an essential tool for intraoperative decision-making and is the focus of a future study.
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F I G U R E 1 Metastatic lobular carcinoma present in sentinel lymph node. In A, H&E stained slide demonstrates a focal pale area on low power corresponding to a 3.0 mm focus metastatic carcinoma (indicated by arrow). In B, tumor cells with relatively bland but larger nuclei are present. In C and D, immunohistochemical stain for pancytokeratin stains the tumor cells
